Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report)'s stock price traded down 7.8% on Tuesday . The company traded as low as $21.12 and last traded at $20.70. 109,994 shares were traded during trading, a decline of 59% from the average session volume of 269,232 shares. The stock had previously closed at $22.46.
Analysts Set New Price Targets
Several brokerages have recently weighed in on ELVN. BTIG Research began coverage on shares of Enliven Therapeutics in a report on Friday, December 13th. They issued a "buy" rating and a $42.00 price objective on the stock. HC Wainwright lifted their price target on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the company a "buy" rating in a research note on Friday, March 21st. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $38.75.
View Our Latest Analysis on ELVN
Enliven Therapeutics Price Performance
The firm has a market capitalization of $1.03 billion, a P/E ratio of -11.09 and a beta of 1.04. The firm's 50 day moving average is $21.28 and its two-hundred day moving average is $23.74.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. Analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.
Insider Activity
In other news, CFO Benjamin Hohl sold 1,000 shares of the stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $25.04, for a total transaction of $25,040.00. Following the sale, the chief financial officer now directly owns 13,000 shares of the company's stock, valued at approximately $325,520. This represents a 7.14 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Anish Patel sold 21,700 shares of the business's stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $24.18, for a total value of $524,706.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 70,434 shares of company stock valued at $1,558,673. 29.20% of the stock is owned by insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. Polar Capital Holdings Plc increased its position in Enliven Therapeutics by 267.6% during the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock worth $53,768,000 after purchasing an additional 1,739,668 shares in the last quarter. Boxer Capital Management LLC bought a new stake in Enliven Therapeutics during the 4th quarter worth $15,106,000. FMR LLC increased its holdings in Enliven Therapeutics by 10.6% in the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company's stock worth $160,804,000 after purchasing an additional 601,611 shares in the last quarter. Lord Abbett & CO. LLC acquired a new stake in shares of Enliven Therapeutics during the third quarter valued at about $8,199,000. Finally, Janus Henderson Group PLC boosted its stake in shares of Enliven Therapeutics by 43.0% during the third quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company's stock valued at $26,611,000 after purchasing an additional 313,019 shares in the last quarter. Institutional investors own 95.08% of the company's stock.
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Further Reading
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
